Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
Social networking helpful for patients, but may need to be vetted
Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments.
Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
FDA Approves Biliary Tract Cancer Antibody Treatment
Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
FDA Approves Bimzelx for Inflammatory Skin Disease
The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.
Read More
Endo Recalls 16 Lots of Clonazepam Due to Mislabeling
A total of 17 lots are now part of the recall of Clonazepam because some cartons have the wrong strength on the label.
Read More
FDA Approves First-in-Class Drug for Rare Leukemia
Relapsed or refractory acute leukemia with a KMT2A translocation currently has an overall survival rate of less than one year when treated with frontline therapies.
Read More
FDA Sets Review Date for Resubmitted Reproxalap in Dry Eye Disease
The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025, for reproxalap for patients with dry eye disease. Reproxalap also is being tested in allergic conjunctivitis.
Read More
FDA Approves Biliary Tract Cancer Antibody Treatment
Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
FDA Approves Bimzelx for Inflammatory Skin Disease
The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.
Read More
Endo Recalls 16 Lots of Clonazepam Due to Mislabeling
A total of 17 lots are now part of the recall of Clonazepam because some cartons have the wrong strength on the label.
Read More
FDA Approves First-in-Class Drug for Rare Leukemia
Relapsed or refractory acute leukemia with a KMT2A translocation currently has an overall survival rate of less than one year when treated with frontline therapies.
Read More
FDA Sets Review Date for Resubmitted Reproxalap in Dry Eye Disease
The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025, for reproxalap for patients with dry eye disease. Reproxalap also is being tested in allergic conjunctivitis.
Read More